258
Participants
Start Date
September 8, 2017
Primary Completion Date
September 5, 2023
Study Completion Date
September 5, 2023
Magrolimab
Administered intravenously
Azacitidine
Administered according to region-specific drug labeling either subcutaneously or intravenously
Weill Cornell Medical College - New York-Presbyterian Hospital, New York
Icahn School of Medicine at Mount Sinai, New York
Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, New York
Montefiore Medical Center, The Bronx
Roswell Park Cancer Institute, Buffalo
University of North Carolina at Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
University Of Miami - Miller School Of Medicine, Sylvester Comprehensive Cancer Center, Miami
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Tennesssee Oncology - Centennial Clinic Location, Nashville
Ohio State University Medical Center, Columbus
Medical College of WI Froedtert Hospital, Milwaukee
The University of Chicago, Chicago
Mid America Division, Inc., Kansas City
Stephenson Cancer Center, Oklahoma City
Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
UCLA Clinical and Translational Research Center (CTRC), Los Angeles
City of Hope National Medical Center, Duarte
University of California San Diego (UCSD), La Jolla
Chao Family Comprehensive Cancer Center - UC Irvine Medical Center, Orange
Stanford University Medical Center, Stanford
University of California Davis Comprehensive Cancer Center, Sacramento
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute/ Boston Children's Hospital, Boston
Oxford Centre for Respiratory Medicine Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford
Lead Sponsor
Gilead Sciences
INDUSTRY